Assessing health outcomes: a systematic review of electronic patient-reported outcomes in oncology.

Autor:	Urretavizcaya M; Pharmacy Department, Onkologikoa, San Sebastian, País Vasco, Spain urretabizkaia.mikel@gmail.com., Álvarez K; Pharmacy Department, Nuestra Senora de la Candelaria University Hospital, Santa Cruz de Tenerife, Canarias, Spain., Olariaga O; Pharmacy Department, Onkologikoa, San Sebastian, País Vasco, Spain., Tames MJ; Pharmacy Department, Onkologikoa, San Sebastian, País Vasco, Spain., Asensio A; Pharmacy Department, Onkologikoa, San Sebastian, País Vasco, Spain., Cajaraville G; Pharmacy Department, Onkologikoa, San Sebastian, País Vasco, Spain., Riestra AC; Pharmacy Department, Onkologikoa, San Sebastian, País Vasco, Spain.; Medicine Department, University of Deusto, Bilbao, País Vasco, Spain.
Jazyk:	angličtina
Zdroj:	European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2024 May 31. Date of Electronic Publication: 2024 May 31.
DOI:	10.1136/ejhpharm-2023-004072
Abstrakt:	Purpose: This study investigates the clinical impact of electronic patient-reported outcome (ePRO) monitoring apps/web interfaces, aimed at symptom-management, in cancer patients undergoing outpatient systemic antineoplastic treatment. Additionally, it explores the advantages offered by these applications, including their functionalities and healthcare team-initiated follow-up programmes. Methods: A systematic literature review was conducted using a predefined search strategy in MEDLINE. Inclusion criteria encompassed primary studies assessing symptom burden through at-home ePRO surveys in adult cancer patients receiving outpatient systemic antineoplastic treatment, whenever health outcomes were evaluated. Exclusion criteria excluded telemedicine-based interventions other than ePRO questionnaires and non-primary articles or study protocols. To evaluate the potential bias in the included studies, an exhaustive quality assessment was conducted, as an additional inclusion filter. Results: Among 246 identified articles, 227 were excluded for non-compliance with inclusion/exclusion criteria. Of the remaining 19 articles, only eight met the rigorous validity assessment and were included for detailed examination and data extraction, presented in attached tables. Conclusion: This review provides compelling evidence of ePRO monitoring's positive clinical impact across diverse cancer settings, encompassing various cancer types, including early and metastatic stages. These systems are crucial in enabling timely interventions and reducing communication barriers, among other functionalities. While areas for future ePRO innovation are identified, the primary limitation lies in comparing clinical outcomes of reviewed articles, due to scale variability and study population heterogeneity. To conclude, our results reaffirm the transformative potential of ePRO apps in oncology and their pivotal role in shaping the future of cancer care. Competing Interests: Competing interests: None declared. (© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu